<DOC>
	<DOCNO>NCT00636493</DOCNO>
	<brief_summary>Purpose : To determine whether fluocinolone acetonide sustain drug delivery implant effective treatment retinal vein occlusion cause persistent macular edema decrease visual acuity . Hypothesis : A fluocinolone acetonide sustain drug delivery implant safe effective method treat patient macular edema decrease vision retinal vein occlusion .</brief_summary>
	<brief_title>Fluocinolone Acetonide Implant Retinal Vein Occlusion ( RVO )</brief_title>
	<detailed_description>Currently limit treatment macular edema vision loss due retinal vein occlusion . Case report show benefit intravitreal steroid injection improve vision reduce macular edema eye retinal vein occlusion . Recently , sustain drug release steroid implant investigate FDA approve treat macular edema patient non-infectious uveitis , eye inflammation . This implant place incision eye wall design deliver steroid , fluocinolone acetonide , upto three year . In animal study detectable steroid see blood stream . This pilot trial recruit individual retinal vein occlusion least one eye . If macular edema vision improve initial intravitreal injection , eye consider receive sustain drug release device . The dosage fluocinolone acetonide use 0.59 mg .</detailed_description>
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Fluocinolone Acetonide</mesh_term>
	<criteria>Patients eligible receive implant meet follow criterion : A history retinal vein occlusion cause macular edema , base clinical evaluation demonstrate fundus photography , fluorescein angiography , optical coherence tomography ( OCT ) Macular edema least one disc area size involve fovea Males nonpregnant female least 18 year age Intraocular Pressure ( IOP ) control &lt; 21 mmHg one topical ocular antihypertensive agent Ability willingness comply treatment follow process understand sign inform consent form . Initially , patient vein occlusion require previous therapy . However , protocol subsequently modify require intravitreal injection triamcinolone acetonide &gt; 12 week prior study entry , initial decrease macular edema improvement visual acuity subsequent decline visual acuity accompany increase macular edema . This modification add avoid enrol patient might longlasting response single intravitreal triamcinolone acetonide injection . Patients exclude allergy fluocinolone acetonide component delivery system , peripheral retinal detachment area implantation , medium opacity preclude evaluation study eye status . Patents disciform scar fovea atrophic change macula investigator 's opinion would preclude benefit treatment exclude study . Female patient pregnant lactate take precaution avoid pregnancy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>retinal vein occlusion</keyword>
	<keyword>sustain drug delivery implant</keyword>
	<keyword>steroid</keyword>
	<keyword>macular edema</keyword>
</DOC>